The $533 Million Generic Drug Settlements Take Claims Until November 9, 2026 — Consumers Can Claim From $475 Million of It, but Only With Proof of Purchase for Each Listed Drug, and Not in Indiana or Ohio

More than ten years of prescriptions, one form. People and health plans that paid for certain generic drugs between May 1, 2009 and December 31, 2019 can now claim money from the end-payer settlements in the generic-drug price-fixing case in Philadelphia. The official site, GenericDrugsEndPayerSettlement.com, run by the court-appointed administrator A.B. Data, states: “To participate in the settlements, you must submit a claim form online or by U.S. Mail so that it is submitted or postmarked by November 9, 2026.” The consumer instructions are just as blunt about the other side of that date: “Any late submissions will not receive any payment from the Settlements.”

The money comes from three sets of defendants. Sandoz Inc. and Fougera Pharmaceuticals agreed to pay $275 million (final approval September 26, 2025). Sun Pharmaceutical Industries and Taro Pharmaceuticals U.S.A. agreed to $200 million (final approval January 23, 2026). Heritage Pharmaceuticals, Emcure Pharmaceuticals, Apotex and one individual defendant settled for $58 million in two agreements. Together that is $533 million by our addition — but the site lists the Apotex and Heritage classes as being for third-party payers only, and the consumer form is titled “Consumer Claim Form for the Sandoz and Sun/Taro Settlements.” For an individual, the pool is therefore the $475 million from Sandoz and Sun/Taro, before fees and costs. All of the settling companies deny liability, and the case, the site says, “remains ongoing against the Non-Settling Defendants.”

The step that opened the claims period came on June 10, 2026, when Judge Cynthia M. Rufe approved the claim forms and the notice plan and appointed A.B. Data as Claims Administrator for all four settlements. Her order set the clock: “All claims must be postmarked or submitted online within 120 days from commencement of Notice.” The site turns that into the November 9 date. As of September 30, 2026 the court-documents pages list no further hearing for the claims process; the fairness hearings on the settlements themselves were held on July 23, 2025 for Sandoz and set for January 15, 2026 for Sun/Taro. The deadlines to object or to opt out have passed.

The class definition is the same for the Sandoz and Sun/Taro consumer claims: “All persons and entities in each of the 50 United States (except Indiana and Ohio), as well as the District of Columbia, Puerto Rico and the U.S. Virgin Islands, that indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price for any Named Generic Drugs, other than for resale, from May 1, 2009 through December 31, 2019.” Three things follow for a consumer. Indiana and Ohio are excluded — the certification you sign says the purchase was made in one of the other states, D.C., Puerto Rico or the Virgin Islands. A copay counts: the class covers anyone who paid “some or all” of the price, and the form tells you to list “the total amount that you paid for the drug, not the amount that your insurer paid.” Cash payers without insurance are in the same position. Medicaid purchases are not: the form excludes “Consumers who were covered by Medicaid for their purchases of Named Generic Drugs.” The remaining exclusions are the defendants' own officers and employees, the judges and their families, people who bought for resale or directly from a defendant, and anyone who opted out earlier.

Then the drug list decides. The form's Appendix A — the current version is dated July 30, 2026 — runs to 197 numbered drugs, from acetazolamide to zoledronic acid, and it names specific forms and strengths, not just molecules. Among the familiar ones: the generic versions of Adderall (amphetamine/dextroamphetamine tablets and extended-release capsules), levothyroxine tablets in twelve strengths, pravastatin, propranolol, warfarin, digoxin, doxycycline, celecoxib, estradiol tablets and clobetasol creams and ointments. The strengths matter. Gabapentin is on the list only as 600 mg and 800 mg tablets. Fluoxetine appears only as tablets. The only metformin entries are an extended-release tablet and combination products with glipizide, glyburide or pioglitazone. Lisinopril, atorvastatin, amlodipine, sertraline and omeprazole do not appear on the July 30 list at all, by our search of it. The site has a drug lookup tool, and the administrator answers questions at 1-877-316-0171.

This is the requirement most people will trip over. For every drug you claim, the form demands “a document (a ‘Proof of Payment’) showing that you purchased that drug at least once from May 1, 2009 to December 31, 2019.” Accepted are receipts or invoices that name the drug, account statements that name the drug, “An itemized record of your purchases that your pharmacy has provided at your request,” and other records showing the purchase and the amount paid. One document per drug proves you bought it; the dollar figure is your own total for the whole period, and if you took several listed strengths of the same drug you add them together. For purchases that are now seven to seventeen years old, a printout from the pharmacy is the realistic route — ask how far back its records go before the deadline gets close.

Be careful with the numbers. You sign under penalty of perjury, and the form warns: “Claims may be audited and rejected because of an inadequate proof of purchase, suspected fraud, or potentially inaccurate amounts, based on expected average purchases.” The administrator may ask for more documents after you file.

You can file online — upload the documents, sign electronically and save the confirmation screen — or on paper to In re: Generic Pharmaceuticals Pricing Antitrust Litigation – End-Payer Settlement, c/o A.B. Data, Ltd., P.O. Box 173118, Milwaukee, WI 53217, postmarked by November 9, 2026. Paper filers who want proof of receipt are told to use certified mail, return receipt requested. The form offers five ways to be paid: ACH direct deposit, Zelle, PayPal, Venmo or a paper check. If your claim is reduced or rejected, you have 14 days from that notice to ask the administrator for another review, and 21 days after its answer to ask the court. A court review is not free of risk: the court may hand the dispute to a special master, and “you may be required to pay 50% of the Special Master's fee.”

There is no official per-person figure. Payments are pro rata by dollars: the Sun/Taro notice says you will be paid “on a pro rata basis in proportion to the amount of money you spent on the Named Generic Drugs from May 1, 2009 through December 31, 2019,” and that if fewer than 100 percent of class members file, shares could grow. The court-approved Sandoz plan spells out the fraction: your eligible purchases divided by “the sum total of all Eligible Purchases (i.e., total amounts paid) by all Eligible Claimants.” Those claimants include third-party payers — insurers and employers or union funds with self-funded drug plans — claiming the part of the same prescriptions they paid. The plan treats the two as separate: an insured consumer's copay and the plan's payment for the balance of the same fill “are not duplicative claims.” A consumer's share is measured only by the copays and cash prices that consumer paid, in the same pool as the health plans' reimbursements.

Before anything is divided, fees and costs come off. For Sandoz, Judge Rufe awarded class counsel one-third of the net fund, $25,700,911.41 in litigation expenses and $410,000 in service awards ($30,000 to each health-plan representative, $5,000 to each consumer representative), with notice and administration counted at up to $750,000. Up to $45 million could go back to Sandoz depending on how many class members opted out. On those figures, and assuming nothing went back to Sandoz, roughly $165 million of the $275 million is left for claimants before interest — our arithmetic, not an official number. For Sun/Taro, the notice allowed counsel to seek up to one-third in fees, up to $4,000,000 in past and future expenses and up to $500,000 in service awards, with administration up to $750,000; the $200 million itself can be reduced by up to $10,000,000 under the agreement. The site lists the court's Sun/Taro fee order of January 23, 2026, but its link did not open a document when we checked on September 30, 2026, so the amounts actually awarded there are not confirmed here.

Two more rules shape small claims. The administrator is to study whether a minimum payment is “feasible and economical” — no floor has been set yet in the documents we read. And the money will not arrive right after November 9: the plan has the administrator review every claim, send deficiency notices with time to fix them, build a payment schedule, and only then does class counsel ask the court for permission to distribute. As of September 30, 2026, no payment date has been announced. Uncashed checks and unclaimed electronic payments are voided after “generally 90 days.”

Judge Rufe's June 10 order told A.B. Data to send postcard and email notices within 30 days, run online banner ads for 45 days for consumers (with Spanish versions), put out a PR Newswire release and print a notice in People magazine. A postcard, email or ad pointing to GenericDrugsEndPayerSettlement.com fits that plan. The real contact points are the site, 1-877-316-0171, info@GenericDrugsEndPayerSettlement.com and P.O. Box 173118, Milwaukee, WI 53217. Type the address yourself instead of following a link. The official form asks for a bank routing and account number only if you choose direct deposit, and it does not ask for any fee.

The sharpest warning comes from the court itself. On November 19, 2025, on a motion about “False and Misleading Communications to Class Members by Claims Recovery Firms,” Judge Rufe ordered 19 named firms and individuals to correct their statements, to tell people that “class members need not sign up for a third-party service to participate in settlements” and that free help with claims is available from the administrator and class counsel, and to clear any future marketing with the court first. Anyone who signed a contract with them “MAY RESCIND THAT CONTRACT,” and the opt-out requests they filed for class members were declared invalid. The settlement site repeats the point: class members “need not sign up with a claims recovery firm or pay another firm in order to participate in the settlements.” Filing is free, and the administrator helps by phone.

The multidistrict litigation, MDL No. 2724 in the Eastern District of Pennsylvania, accuses dozens of generic-drug companies — the notice lists defendants from Actavis and Amneal to Teva, Mylan, Pfizer, Greenstone, Lupin, Dr. Reddy's and Zydus — of schemes “to fix, maintain and stabilize prices, rig bids, and engage in market and customer allocation” of the listed drugs. Those are allegations; the defendants deny them, and the notice stresses that “No trial has been held.” Sandoz, Sun/Taro, Heritage and Apotex settled; the claims against the others continue, and Sun and Taro agreed to cooperate with the plaintiffs against the non-settling defendants. Separately, the court certified two litigation classes for third-party payers over clomipramine and clobetasol, and state attorneys general pursue their own cases — the Sun/Taro notice warns that its release “may affect your ability to recover against Sun/Taro in certain cases brought by the Attorneys General of some States.”

If you do nothing, the site says, you “will not get a payment from the Settlement and will give up your right to sue Sun or Taro on your own for the same legal claims made in this lawsuit.” The same logic applies to Sandoz. If you have a pharmacy record for even one listed drug from those years, this generic drug settlement costs only the time it takes to file by November 9, 2026. The Sun/Taro notice described its own payout as “likely in conjunction with the proceeds of other settlements.”